Breast Cancer Research Report SWAG Site Specific Group Clinical Research Network West of England Breast Cancer Research Report SWAG Site Specific Group Friday 1st July 2016 Maxine Taylor Senior Research Delivery Manager - Cancer
South West Research Networks & SWAG West of England SWAG South West Peninsula
Local Clinical Research Networks Translation of national objectives for clinical research Oversight of research activity within the geography of CRN - West of England in terms of: Portfolio Balance, new studies, feasibility, industry trials Performance Support, network wide solutions, targets People Patient involvement, staff skill mix & flexibility, training, resources
National objectives Timely set up of studies Recruitment to time and target Include commercial research
Objectives for cancer Recruit 20% of cancer incidence Recruit 7.5% of cancer incidence into interventional studies Include challenging studies Children and TYA cancers Rare cancers Surgical studies Radiotherapy studies
National recruitment to breast cancer studies by local network 2015-16
Recruiting studies 2015-16
Recruiting studies 2016-17 StudyDesignType Short Name GREAT WESTERN HOSPITALS NHS FOUNDATION TRUST NORTH BRISTOL NHS TRUST ROYAL UNITED HOSPITALS BATH NHS FOUNDATION TRUST TAUNTON AND SOMERSET NHS FOUNDATION TRUST UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST WESTON AREA HEALTH NHS TRUST YEOVIL DISTRICT HOSPITAL NHS FOUNDATION TRUST Grand Total Both MAMMO-50 1 6 2 12 Both Total Interventional A multi-centred-study of the effectiveness of PEGASUS 7 CONCEPT (Breast Cancer) FURVA, Version 1.0 3 5 8 MANTA NCRN - 3156 POSNOC ROSCO Interventional Total 4 31 Observational CANC - 3831 MBC - disease registry study Chemo-NEAR Observational Total 9 15 45
Viewing the portfolio http://csg.ncri.org.uk/portfolio/portfolio-maps/ IBIS 3 An International Breast Intervention Study investigating Prevention Of Late Recurrence in ER+ breast cancer survivors following 5 years of adjuvant treatment Baronet Biological and radiological outcomes of neoadjuvant endocrine treatment BLUEBELL A proof of concept phase II study of Buparlisib in HER2 positive breast cancer with brain metastasis following HER2 directed monoclonal antibody therapy
Contacts West of England Breast cancer (oncology) specialty lead – mark.beresford@nhs.net Breast cancer (surgery) specialty lead – zenon.rayter@nbt.nhs.uk Research Delivery Manager – maxine.taylor@nihr.ac.uk Cancer portfolio facilitator – richard.munday@nihr.ac.uk South West Peninsula Breast cancer specialty lead – duncan.wheatley@rcht.cornwall.nhs.uk Cancer Research Delivery Manager - Julie.cunningham4@nhs.net